HCV Policy & Advocacy
EASL 2017: European HCV Treatment Access Survey Shows Big Variations in Eligibility
- Details
- Category: HCV Policy & Advocacy
- Published on Friday, 21 April 2017 00:00
- Written by Keith Alcorn
England, Malta, Slovakia, Hungary, and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland, and the Netherlands are the least restrictive, according to research presented at the International Liver Congress this week in in Amsterdam, the annual meeting of the European Association for the Study of the Liver (EASL).
HIV Glasgow: Tests of Online PrEP Purchases Find No Fakes and Adequate Drug Levels
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 01 November 2016 00:00
- Written by Gus Cairns
A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate levels of both drugs in their blood, and no sample suggesting counterfeit drugs.
HIV Glasgow: French Study Reveals Growing Complexity of Medical Needs as People with HIV Age
- Details
- Category: HIV-Related Conditions
- Published on Friday, 28 October 2016 00:00
- Written by Keith Alcorn
The complexity of the needs of people living with HIV will continue to increase as the population ages, and clinicians need to go beyond thinking about co-morbidities to consider multi-morbidities -- clusters of medical conditions that complicate one another -- when caring for these people, Edouard Battegay from the University Hospital Zurich told attendees at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week.
HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates
- Details
- Category: HCV Treatment
- Published on Saturday, 29 October 2016 00:00
- Written by Keith Alcorn
Use of generic versions of direct-acting antivirals for hepatitis C resulted in very high cure rates for people who obtained the products through 3 buyers’ clubs, indicating that the generic products are effective, according to a set of poster presentations at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week. People who purchased generic drugs were cured at a cost of around US$700-$900 in Southeast Asia and Eastern Europe, Andrew Hill of St. Stephen’s AIDS Trust reported.
HIV Glasgow: Dolutegravir and Central Nervous System Side-Effects -- Abacavir, Older Age Increase the Risk
- Details
- Category: Approved HIV Drugs
- Published on Friday, 28 October 2016 00:00
- Written by Keith Alcorn
Insomnia, dizziness, headache, and other central nervous system (CNS) side effects are occurring more frequently with everyday use of dolutegravir than clinical trials had suggested, and are most likely to occur among women, people over age 60, and people starting abacavir at the same time, a German research group reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) this week.
More Articles...
- HIV Glasgow: New $90-$90-$90 Target Needed for Global Viral Hepatitis, HIV, and TB Treatment
- INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment
- INHSU 2016: HCV Treatment Effective and May Work as Prevention for People Who Inject Drugs
- INHSU 2016 Opens with Focus on Hepatitis C Prevention and Treatment for People Who Inject Drugs
Web Design and Development by